ArticleDiabetes & vascular disease research
Serum LINC00861: A novel biomarker for diabetic nephropathy diagnosis and a promoter of renal injury via miR-378a-3p.
Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study investigated the expression and diagnostic significance of LINC00861 in DN and explored its functional mechanisms in high glucose-induced cell damage.MethodsWe enrolled 285 participants: 92 healthy controls, 98 uncomplicated T2DM patients, and 95 DN patients. Serum LINC00861 and miR-378a-3p levels were measured via qRT-PCR. Correlations with clinical parameters were assessed using Pearson analysis. Logistic regression identified risk factors for DN progression, and ROC curves evaluated diagnostic accuracy. In vitro, LINC00861 was knocked down to assess its effects on proliferation, inflammation, and oxidative stress under high glucose. Targeting of miR-378a-3p was confirmed by dual-luciferase and RIP assays.ResultsThe LINC00861 expression was significantly elevated in DN patients compared to T2DM and healthy controls, and correlated positively with FBG, HbA1c, and albuminuria, but negatively with eGFR. Multivariate analysis identified LINC00861 as an independent risk factor for DN. The AUC for distinguishing T2DM from DN was 0.918. miR-378a-3p expression was significantly lower in DN patients than in those with T2DM or healthy controls. LINC00861 silencing may alleviate HG induced aberrant proliferation, inflammatory responses, and oxidative stress, possibly via the regulation of miR-378a-3p.ConclusionThe LINC00861 is upregulated in DN and may facilitate renal injury by sponging miR-378a-3p, indicating its potential as a diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.